Home > Urology > EAU 2019 > Prostate Cancer > Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer

Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer

Presented By
Prof. Antonio Alcaraz, Prof. Noel Clarke
Conference
EAU 2019
Trial
Phase 3, ARCHES
Results from the large international phase 3 ARCHES trial show that, in men with metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide combined with androgen deprivation therapy (ADT) significantly extended radiographic progression-free survival (rPFS) compared with ADT alone. Enzalutamide has already demonstrated a benefit in men with metastatic and localised castration-resistant prostate cancer (CRPC), but its efficacy when combined with ADT in mHSPC patients has remained unclear. Executed worldwide at sites in the United States, Canada, Europe, South America, and the Asia-Pacific region, the ARCHES trial was a randomised, double-blind, placebo-controlled, international study that enrolled 1,150 mHSPC patients. Patients treated by ADT (with luteinising hormone-releasing hormone agonist or antagonist, or bilateral orchiectomy) were randomised to either receive a daily dose of 160 m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on